MedPath

Atropine

Generic Name
Atropine
Brand Names
Atnaa, Atropen, Busulfex, Donnatal, Duodote, Enlon-plus, Isopto Atropine, Lomotil, Minims Atropine Sulphate, Motofen, Phenohytro
Drug Type
Small Molecule
Chemical Formula
C17H23NO3
CAS Number
51-55-8
Unique Ingredient Identifier
7C0697DR9I

Overview

Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products. Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters. It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.

Background

Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products. Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters. It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.

Indication

The intravenous, intramuscular, subcutaneous, intraosseous and endotracheal use of atropine is indicated for the temporary blockade of severe or life-threatening muscarinic effects. The intramuscular use of atropine in the form of a pen injector is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. The ophthalmic use of atropine is indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia. In combination with difenoxin or diphenoxylate (tablets for oral use), atropine is indicated as adjunctive therapy in the management of acute nonspecific diarrhea.

Associated Conditions

  • Amblyopia
  • Atrioventricular Heart-block
  • Bradycardia
  • Bronchospasm
  • Crying
  • Detrusor Hyperreflexia
  • Excessive bronchial secretion
  • Hypertonic uterine contraction
  • Hypertonicity of the small intestine
  • Ocular Inflammation
  • Parkinsonism
  • Peptic Ulcer
  • Poisoning by parasympathomimetics (cholinergics)
  • Poisoning caused by mushrooms
  • Poisoning caused by organophosphate anticholinesterase nerve agents
  • Poisoning caused by organophosphorus pesticides
  • Pylorospasm
  • Rhinorrhoea
  • Sinus Bradycardia
  • Spasms
  • Toxic effect of organophosphate and carbamate
  • Hypermobility of the colon
  • Laughing
  • Life-threatening muscarinic side effects
  • Muscarinic side effects
  • Severe muscarinic side effects

FDA Approved Products

Atropine Sulfate
Manufacturer:A-S Medication Solutions
Route:PARENTERAL
Strength:0.1 mg in 1 mL
Approved: 2016/11/18
NDC:50090-3138
Atropine Sulfate
Manufacturer:Henry Schein, Inc.
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/09/05
NDC:0404-9989
Atropine Sulfate
Manufacturer:Medefil, Inc.
Route:INTRAVENOUS
Strength:0.1 mg in 1 mL
Approved: 2023/05/18
NDC:64253-400
Atropine
Manufacturer:Akorn
Route:OPHTHALMIC
Strength:10 mg in 1 mL
Approved: 2014/07/15
NDC:17478-215
ATROPINE SULFATE
Manufacturer:HF Acquisition Co LLC, DBA HealthFirst
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:1 mg in 1 mL
Approved: 2021/06/14
NDC:51662-1509

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath